Ahmedabad-based Torrent Pharma released its Q1 FY26 results on Monday, reporting an 11% year-on-year (YoY) revenue growth of Rs 3,178 crore from the corresponding period’s Rs 2,859 crore.
Its operating earnings before interest, taxes, depreciation and amortisation (EBIDTA) increased 14% this quarter to Rs 1,032 crore from Q1 FY25’s 904 crore, which includes an acquisition related to one-off expenses of Rs 15 crore. The gross margin stands at 76% while the operating EBITDA stands at 32.5%.
Profit after taxes (PAT) for the pharmaceutical company was recorded at Rs 548 crore, a 20% growth from the corresponding period’s Rs 457 crore.
Strong domestic growth
In a media release, the company’s India revenue was up by 11% to Rs 1,811 crore due to an outperformance in focus therapies, while its chronic business grew by 13% compared to the Indian Pharmaceutical Market’s (IPM) growth of 9%. 21 of Torrent’s brands fall in the Top 500 brands in the IPM, with 14 of those brands generating over Rs 100 crores in sales.
Robust international performance
Torrent’s international revenues also witnessed substantial growth this quarter, with Brazil revenues up by 11% to Rs 218 crores, Germany’s revenues growing 9% to Rs 308 crores and US revenues rising by 19% to Rs 308 crores.
Growth in Brazil was aided by the performance of Torrent’s top brands and new launches, with 62 more products under the Brazil Health Regulatory Agency’s review. Growth in Germany was impacted due to a supply disruption by a third-party supplier, while Torrent’s recent launches in the US market have achieved targeted market shares.
Shares of the company grew by 0.73% at the NSE, closing at Rs 3,630.00 from yesterday’s close of Rs 3,603.800.